Table 1 Characteristics of 48 inpatients who had done mNGS testing.
No. (%) | Mean ± SD/Median (IQR) | |
|---|---|---|
Age | 40.3 ± 13.4 | |
Male | 44 (91.7) | |
Marital status | ||
Married | 25 (52.1) | |
Single | 18 (37.5) | |
Divorced/Widowed | 5 (10.4) | |
Past medical history | ||
HBV infection | 6 (12.5) | |
HCV infection | 3 (6.3) | |
Syphilis | 16 (33.3) | |
Tuberculosis | 3 (6.3) | |
Cardiovascular and cerebrovascular diseases | 2 (4.2) | |
Routes of HIV acquisition | ||
Sexually transmission | 44 (91.7) | |
Blood-borne transmission | 4 (8.3) | |
cART coverage | 39 (81.3) | |
Symptoms and signs | ||
Headache | 24 (50.0) | |
Fever | 23 (47.9) | |
Nausea | 15 (31.3) | |
Consciousness disorder | 8 (16.7) | |
Blurred vision | 6 (12.5) | |
Seizure | 5 (10.4) | |
Dyspnea | 1 (2.1) | |
Neck stiffness | 1 (2.1) | |
Days from illness onset to first admission | 20 (14, 30) | |
Days of hospital stay | 17 (14, 25) | |
LgHIV-VL | 4.4 (3.6, 5.1) | |
Died within 12 weeks | 4 (8.3) | |
Abnormal CT or MRI scan of brain | 38 (79.2) | |
Blood routine and biochemistry results | ||
White blood cell count, × 109/L | 4.22 ± 1.96 | |
< 4.0 × 109/L | 22 (45.8) | |
> 10.0 × 109/L | 1 (2.1) | |
Neutrophil count, × 109/L | 2.7 (1.4, 3.8) | |
Lymphocyte count, × 109/L | 0.7 (0.4, 1.2) | |
< 1.0 × 109/L, No. (%) | 26 (54.2) | |
Hg, g/L | 109.8 ± 25.4 | |
< 90 g/L | 9 (18.8) | |
Platelet count, × 109/L | 181.9 ± 96.2 | |
< 100 × 109/L | 11 (23.0) | |
Alanine aminotransferase, U/L | 21 (14.3, 39.3) | |
> 50U/L | 9 (18.8) | |
Aspartate aminotransferase, U/L | 27 (19.3, 49.8) | |
> 40U/L | 14 (29.2) | |
Albumin, g/L | 33.7 (27.2, 9.6) | |
< 40 g/L | 39 (81.3) | |
Globulin, g/L | 35.8 ± 6.5 | |
> 30 g/L | 40 (83.3) | |
Creatinine, μmol/L | 5.6 (4.1, 7.4) | |
> 104 μmol/L | 6 (12.5) | |
Urea nitrogen, mmol/L | 5.6 (4.1, 7.4) | |
> 7.6 mmol/L | 10 (20.8) | |
CYSC, mg/L | 1.0 (0.9, 1.2) | |
> 1.2 mg/L | 14 (29.2) | |
Lymphocyte subsets and NK cells in peripheral blood | ||
CD3 + T cell | 370.5 (242.0, 690.5) | |
CD3 + CD4 + %Lym | 6.9 (3.8, 10.0) | |
CD3 + CD4 + Abs | 34.0 (13.0, 122.5) | |
CD3 + CD8 + %Lym | 61.2 (53.3, 61.2) | |
CD3 + CD8 + Abs | 406.5 (208.5, 564.0) | |
CD4 + /CD8 + Ratio | 0.12 (0.07, 0.18) | |
CD19 + %Lym | 9.0 (5.0, 14.3) | |
CD19 + B cell | 58.5 (22.5, 77.5) | |
CD16 + CD56 + % NK cell | 11.0 (7.3, 16.3) | |
CD16 + CD56 + Abs | 76.5 (39.0, 104.0) | |
Lactate dehydrogenase, U/L | 211.0 (169.0, 480.5) | |
> 243U/L | 18 (37.5) | |
D-dimer, ng/mL | 440.0 (205.0, 854.8) | |
> 500 ng/mL | 22 (45.8) | |
Infection-related biomarkers | ||
ESR, mm/h | 34.9 ± 23.9 | |
> 15 mm/h | 31 (64.6) | |
C-reactive protein, mg/L | 20.0 (5.8, 71.6) | |
> 10 mg/L | 17 (35.4) | |
Interleukin-6, pg/mL | 11.6 (6.4, 31.6) | |
> 7 pg/mL | 25 (52.1) | |
Procalcitonin, ng/mL | 0.06 (0.05, 0.32) | |
> 1.0 ng/mL | 7(14.6) | |
